Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-Analysis

Young Sik Kim, Hoiseon Jeong, Jung-Woo Choi, Hwa Oh, Ju-Han Lee

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background/Aim: Recently, AT-rich interactive domain-containing 1A protein (ARID1A) has been identified as a novel tumor suppressor gene in gastric cancer (GC) and colorectal cancer (CRC). However, the clinicopathologic value of ARID1A mutation or protein level in GC and CRC patients is controversial. Hence, we conducted a meta-Analysis on the relationship between ARID1A aberrations and clinicopathologic parameters in GC and CRC. Materials and Methods: Relevant published studies were selected from PubMed and EMBASE. The effect sizes of ARID1A mutation or level on the patient's clinicopathologic parameters were calculated by prevalence rate or odds ratio (OR) or hazard ratio (HR), respectively. The effect sizes were combined using a random-effects model. Results: The frequency of ARID1A mutation and loss of ARID1A protein expression in GC patients was 17% and 27%, respectively. The loss of ARID1A protein expression of GC patients was significantly associated with advanced tumor depth (OR = 1.8, P = 0.004), lymph node metastasis (OR = 1.4, P = 0.001), and unfavorable adjusted overall survival (HR = 1.5, P < 0.001). ARID1A mutation of GC was significantly associated with microsatellite instability (MSI) (OR = 24.5, P < 0.001) and EBV infection (OR = 2.6, P = 0.001). The frequency of ARID1A mutation and ARID1A protein expression loss in CRC patients was approximately 12-13%. Interestingly, the loss of ARID1A protein expression in CRC patients was significantly associated with poorly differentiated grade (OR = 4.0, P < 0.001) and advanced tumor depth (OR = 1.8, P = 0.012). Conclusion: Our meta-Analysis revealed that ARID1A alterations may be involved in the carcinogenesis of GC by EBV infection and MSI. The loss of ARID1A protein expression may be a marker of poor prognosis in GC and CRC patients.

Original languageEnglish
Pages (from-to)268-274
Number of pages7
JournalSaudi Journal of Gastroenterology
Volume23
Issue number5
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Stomach Neoplasms
Meta-Analysis
Colorectal Neoplasms
Mutation
Proteins
Odds Ratio
Microsatellite Instability
Epstein-Barr Virus Infections
Tumor Suppressor Genes
PubMed

Keywords

  • ARID1A
  • colorectal cancer
  • gastric cancer
  • meta-Analysis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer : A meta-Analysis. / Kim, Young Sik; Jeong, Hoiseon; Choi, Jung-Woo; Oh, Hwa; Lee, Ju-Han.

In: Saudi Journal of Gastroenterology, Vol. 23, No. 5, 01.09.2017, p. 268-274.

Research output: Contribution to journalReview article

@article{cef2855c6f0d4c6f945eb0394cdfdf94,
title = "Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-Analysis",
abstract = "Background/Aim: Recently, AT-rich interactive domain-containing 1A protein (ARID1A) has been identified as a novel tumor suppressor gene in gastric cancer (GC) and colorectal cancer (CRC). However, the clinicopathologic value of ARID1A mutation or protein level in GC and CRC patients is controversial. Hence, we conducted a meta-Analysis on the relationship between ARID1A aberrations and clinicopathologic parameters in GC and CRC. Materials and Methods: Relevant published studies were selected from PubMed and EMBASE. The effect sizes of ARID1A mutation or level on the patient's clinicopathologic parameters were calculated by prevalence rate or odds ratio (OR) or hazard ratio (HR), respectively. The effect sizes were combined using a random-effects model. Results: The frequency of ARID1A mutation and loss of ARID1A protein expression in GC patients was 17{\%} and 27{\%}, respectively. The loss of ARID1A protein expression of GC patients was significantly associated with advanced tumor depth (OR = 1.8, P = 0.004), lymph node metastasis (OR = 1.4, P = 0.001), and unfavorable adjusted overall survival (HR = 1.5, P < 0.001). ARID1A mutation of GC was significantly associated with microsatellite instability (MSI) (OR = 24.5, P < 0.001) and EBV infection (OR = 2.6, P = 0.001). The frequency of ARID1A mutation and ARID1A protein expression loss in CRC patients was approximately 12-13{\%}. Interestingly, the loss of ARID1A protein expression in CRC patients was significantly associated with poorly differentiated grade (OR = 4.0, P < 0.001) and advanced tumor depth (OR = 1.8, P = 0.012). Conclusion: Our meta-Analysis revealed that ARID1A alterations may be involved in the carcinogenesis of GC by EBV infection and MSI. The loss of ARID1A protein expression may be a marker of poor prognosis in GC and CRC patients.",
keywords = "ARID1A, colorectal cancer, gastric cancer, meta-Analysis",
author = "Kim, {Young Sik} and Hoiseon Jeong and Jung-Woo Choi and Hwa Oh and Ju-Han Lee",
year = "2017",
month = "9",
day = "1",
doi = "10.4103/sjg.SJG_184_17",
language = "English",
volume = "23",
pages = "268--274",
journal = "Saudi Journal of Gastroenterology",
issn = "1319-3767",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "5",

}

TY - JOUR

T1 - Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer

T2 - A meta-Analysis

AU - Kim, Young Sik

AU - Jeong, Hoiseon

AU - Choi, Jung-Woo

AU - Oh, Hwa

AU - Lee, Ju-Han

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background/Aim: Recently, AT-rich interactive domain-containing 1A protein (ARID1A) has been identified as a novel tumor suppressor gene in gastric cancer (GC) and colorectal cancer (CRC). However, the clinicopathologic value of ARID1A mutation or protein level in GC and CRC patients is controversial. Hence, we conducted a meta-Analysis on the relationship between ARID1A aberrations and clinicopathologic parameters in GC and CRC. Materials and Methods: Relevant published studies were selected from PubMed and EMBASE. The effect sizes of ARID1A mutation or level on the patient's clinicopathologic parameters were calculated by prevalence rate or odds ratio (OR) or hazard ratio (HR), respectively. The effect sizes were combined using a random-effects model. Results: The frequency of ARID1A mutation and loss of ARID1A protein expression in GC patients was 17% and 27%, respectively. The loss of ARID1A protein expression of GC patients was significantly associated with advanced tumor depth (OR = 1.8, P = 0.004), lymph node metastasis (OR = 1.4, P = 0.001), and unfavorable adjusted overall survival (HR = 1.5, P < 0.001). ARID1A mutation of GC was significantly associated with microsatellite instability (MSI) (OR = 24.5, P < 0.001) and EBV infection (OR = 2.6, P = 0.001). The frequency of ARID1A mutation and ARID1A protein expression loss in CRC patients was approximately 12-13%. Interestingly, the loss of ARID1A protein expression in CRC patients was significantly associated with poorly differentiated grade (OR = 4.0, P < 0.001) and advanced tumor depth (OR = 1.8, P = 0.012). Conclusion: Our meta-Analysis revealed that ARID1A alterations may be involved in the carcinogenesis of GC by EBV infection and MSI. The loss of ARID1A protein expression may be a marker of poor prognosis in GC and CRC patients.

AB - Background/Aim: Recently, AT-rich interactive domain-containing 1A protein (ARID1A) has been identified as a novel tumor suppressor gene in gastric cancer (GC) and colorectal cancer (CRC). However, the clinicopathologic value of ARID1A mutation or protein level in GC and CRC patients is controversial. Hence, we conducted a meta-Analysis on the relationship between ARID1A aberrations and clinicopathologic parameters in GC and CRC. Materials and Methods: Relevant published studies were selected from PubMed and EMBASE. The effect sizes of ARID1A mutation or level on the patient's clinicopathologic parameters were calculated by prevalence rate or odds ratio (OR) or hazard ratio (HR), respectively. The effect sizes were combined using a random-effects model. Results: The frequency of ARID1A mutation and loss of ARID1A protein expression in GC patients was 17% and 27%, respectively. The loss of ARID1A protein expression of GC patients was significantly associated with advanced tumor depth (OR = 1.8, P = 0.004), lymph node metastasis (OR = 1.4, P = 0.001), and unfavorable adjusted overall survival (HR = 1.5, P < 0.001). ARID1A mutation of GC was significantly associated with microsatellite instability (MSI) (OR = 24.5, P < 0.001) and EBV infection (OR = 2.6, P = 0.001). The frequency of ARID1A mutation and ARID1A protein expression loss in CRC patients was approximately 12-13%. Interestingly, the loss of ARID1A protein expression in CRC patients was significantly associated with poorly differentiated grade (OR = 4.0, P < 0.001) and advanced tumor depth (OR = 1.8, P = 0.012). Conclusion: Our meta-Analysis revealed that ARID1A alterations may be involved in the carcinogenesis of GC by EBV infection and MSI. The loss of ARID1A protein expression may be a marker of poor prognosis in GC and CRC patients.

KW - ARID1A

KW - colorectal cancer

KW - gastric cancer

KW - meta-Analysis

UR - http://www.scopus.com/inward/record.url?scp=85029761476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029761476&partnerID=8YFLogxK

U2 - 10.4103/sjg.SJG_184_17

DO - 10.4103/sjg.SJG_184_17

M3 - Review article

C2 - 28937020

AN - SCOPUS:85029761476

VL - 23

SP - 268

EP - 274

JO - Saudi Journal of Gastroenterology

JF - Saudi Journal of Gastroenterology

SN - 1319-3767

IS - 5

ER -